ETH Zürich - Numerische Materialmodellierung
8005 Zürich, Technoparkstrasse 1 / Einstein PFA G 11 (2. OG)
ETH Zürich - Numerische Materialmodellierung
Technoparkstrasse 1
8005 Zürich
10 Ergebnisse für "chemotherapeutic" unter ETH Zürich - Numerische Materialmodellierung
Next-generation DNA damage sequencing - Research Collection
... ; oxidative stress, chemotherapeutic drugs, environmental pollutants, and sun exposure. Preferred sequences ... evaluate and predict the efficacy of chemotherapeutic drugs. Show more Permanent link More Cited 24 times ... , chemotherapeutic drugs, environmental pollutants, and sun exposure. Preferred sequences for damage formation and ... efficacy of chemotherapeutic drugs. Show more Permanent link https://doi.org/10.3929/ethz-b-000448689 ...
Platinum nanoparticles for selective treatment of liver cancer cell...
... of comments Liver tumours are treated with chemotherapeutic agents that do not specifically target ... chemotherapeutic agents still play an important role in cancer treatment. These include platinum-based cytotoxic ... . 14.02.2019 by Oliver Renn mode_comment Number of comments Liver tumours are treated with chemotherapeutic ... rise. However, conventional chemotherapeutic agents still play an important role in cancer treatment ...
ETH Zürich - Feasibility Lab
Technoparkstrasse 1
8005 Zürich
10 Ergebnisse für "chemotherapeutic" unter ETH Zürich - Feasibility Lab
Platinum nanoparticles for selective treatment of liver cancer cell...
... mode_comment Number of comments Liver tumours are treated with chemotherapeutic agents that do not ... chemotherapeutic agents still play an important role in cancer treatment. These include platinum-based cytotoxic ... mode_comment Number of comments Liver tumours are treated with chemotherapeutic agents that do not specifically ... chemotherapeutic agents still play an important role in cancer treatment. These include platinum-based cytotoxic ...
Infozentrum: Catalog
... : From Chemotherapeutic to Hyperthermia-Based Therapy Nanomedicine for Cancer Therapy : From ... Chemotherapeutic to Hyperthermia-Based Therapy Classification Publisher Medium Nanomedicine for Inflammatory ... and Technology : Nanotheranostics Nanomedicine for Cancer Therapy : From Chemotherapeutic to ... Technology : Nanotheranostics Nanomedicine for Cancer Therapy : From Chemotherapeutic to Hyperthermia-Based ...
ANSYS Switzerland GmbH
8005 Zürich, Technoparkstrasse 1 / Zeppelin 3003
+41 44 500 93 60
ANSYS ist der weltweit führende Anbieter von technischen Simulationslösungen und entwickelt, vertreibt und unterstützt Software für Engineering Simulation. Was ANSYS auszeichnet und von anderen professionellen Berechnungsprogrammen abhebt, ist unter anderem seine Multiphysikfähigkeit. Es kann neben Mechanik und Heattransfer ebenso Fluidynamik, Akustik und Elektromagnetik berechnet werden. Auch die gleichzeitige gekoppelte Behandlung dieser physikalischen Aspekte in einer Simulation ist abgedeckt.
ANSYS Switzerland GmbH
Technoparkstrasse 1
8005 Zürich
5 Ergebnisse für "chemotherapeutic" unter ANSYS Switzerland GmbH
Targeting a Tumor | Healthcare | ANSYS Advantage
... increasing the accuracy of delivering a chemotherapeutic drug to a lung tumor to 90 percent, versus 20 ... advance the field of personalized medicine. By increasing the accuracy of delivering a chemotherapeutic ... chemotherapeutic drug to a lung tumor to 90 percent, versus 20 percent by conventional aerosol methods, they have ... advance the field of personalized medicine. By increasing the accuracy of delivering a chemotherapeutic ...
Targeting a Tumor | Healthcare | ANSYS Advantage
... increasing the accuracy of delivering a chemotherapeutic drug to a lung tumor to 90 percent, versus 20 ... advance the field of personalized medicine. By increasing the accuracy of delivering a chemotherapeutic ... chemotherapeutic drug to a lung tumor to 90 percent, versus 20 percent by conventional aerosol methods, they have ... advance the field of personalized medicine. By increasing the accuracy of delivering a chemotherapeutic ...
